John Rockefeller
Internal Medicine · Topeka, KSNPI 1538108071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 25.7% of the total.
Across 82 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$328
- Lilly USA, LLC$180
- Novo Nordisk$95
- CSL Behring$91
- Genentech USA, Inc.$84
- Conformis, Inc.$79
- plus $419 from 13 others
What the payments were for
- Food & beverage$1,25298%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $328 |
| Lilly USA, LLC | 15 | $180 |
| Novo Nordisk | 7 | $95 |
| CSL Behring | 7 | $91 |
| Genentech USA, Inc. | 7 | $84 |
| Conformis, Inc. | 1 | $79 |
| Pharming Healthcare, Inc. | 5 | $78 |
| Shire North American Group Inc | 5 | $69 |
| Astellas Pharma US Inc | 3 | $38 |
| AbbVie | 2 | $36 |
| Boehringer Ingelheim | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Pfizer | 2 | $26 |
| Novartis | 2 | $25 |
| Amgen | 2 | $25 |
| GSK | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$1,275 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $4,223 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $224 |
| Atorvastatin Calcium | 29 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $4,22329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Topeka
- Michael CoxTopeka$10K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.